- Price
- $3.15
- Day
- +6.78%
- Mkt Cap
- $291.92M
- 52W Range
- $2.26 – $11.70
- Volume
- 1.98M
- Beta
- 1.14
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Nominates Two New Independent Directors, Mr. Gautam Patel and Dr. Adrian Senderowicz, Who Bring Deep, Relevant Experience in Life Sciences
Read full article
NEW YORK, July 30, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (Anavex or the Company) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system (CNS) diseases with high unmet medical needs, today reported preliminary financial results for its fiscal second quarter ended March 31, 2026. The Company's primary focus is on advancing its lead compound ANAVEX®2-73 (blarcamesine) in the Company's clinical program for the treatment of mild cognitive impairment (“MCI”) due to Alzheimer's disease (“AD”) and mild AD (collectively known as “early AD”), and for Rett syndrome and Fragile X syndrome, both of which are neurodevelopmental rare diseases.
Read full article